Akari Therapeutics Plc (Akari), formerly Celsus Therapeutics Plc, is a biopharmaceutical company which focuses on the development and commercialization of treatments for rare and orphan autoimmune and inflammatory diseases. Its lead drug, coversin, an inhibitor, acts on complement component-C5 that helps in preventing the release of C5a and formation of C5b-9. The company's pipeline product portfolio includes paroxysmal nocturnal hemoglobinuria; Guillain Barre Syndrome and atypical hemolytic uremic syndrome. Akari focuses on the rare and orphan diseases that include spanning hematology, nephrology, transplantation, neurology and ophthalmology. The company operates through its subsidiaries in Delware, London, Switzerland, and Israel. Akari is headquartered in New York, the US.
Akari Therapeutics Plc Key Recent Developments
Jan 04, 2017: Akari Therapeutics Expands Clinical and Regulatory Teams with Industry Veterans
Oct 14, 2016: Akari Therapeutics Appoints New Members to its Board of Directors
This comprehensive SWOT profile of Akari Therapeutics Plc provides you an in-depth strategic analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
This company report forms part of GlobalData's 'Profile on Demand' service, covering over 50,000 of the world's leading companies. Once purchased, GlobalData's highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Akari Therapeutics Plc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).
The profile contains critical company information including*,
Business description-A detailed description of the company's operations and business divisions.
Corporate strategy-Analyst's summarization of the company's business strategy.
SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.
Company history-Progression of key events associated with the company.
Major products and services-A list of major products, services and brands of the company.
Key competitors-A list of key competitors to the company.
Key employees-A list of the key executives of the company.
Executive biographies-A brief summary of the executives' employment history.
Key operational heads-A list of personnel heading key departments/functions.
Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.
Key manufacturing facilities-A list of key manufacturing facilities of the company.
Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Note*: Some sections may be missing if data is unavailable for the company.
Key benefits of buying this profile include,
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Section 1-About the Company
Akari Therapeutics Plc-Key Information
Akari Therapeutics Plc-Overview
Akari Therapeutics Plc-Key Employees
Akari Therapeutics Plc-Key Employee Biographies
Akari Therapeutics Plc-Key Operational Heads
Akari Therapeutics Plc-Major Products and Services
Akari Therapeutics Plc-History
Akari Therapeutics Plc-Company Statement
Akari Therapeutics Plc-Locations And Subsidiaries
Akari Therapeutics Plc-Key Manufacturing facilities
Other Locations & Subsidiaries
Section 2-Company Analysis
Akari Therapeutics Plc-Business Description
Akari Therapeutics Plc-Corporate Strategy
Akari Therapeutics Plc-SWOT Analysis
Akari Therapeutics Plc-Strengths
Akari Therapeutics Plc-Weaknesses
Akari Therapeutics Plc-Opportunities
Akari Therapeutics Plc-Threats
Akari Therapeutics Plc-Key Competitors
Section 3-Company Financial Performance Charts
Akari Therapeutics Plc-Financial Ratios
Financial Ratios-Capital Market Ratios
Financial Ratios-Annual Ratios
Financial Ratios-Interim Ratios
Financial Ratios-Ratio Charts
Note*: Some sections may be missing if data is unavailable for the company
List of Figures
Akari Therapeutics Plc, Performance Chart
Akari Therapeutics Plc, Ratio Charts
List of Tables
Akari Therapeutics Plc, Key Information
Akari Therapeutics Plc, Key Ratios
Akari Therapeutics Plc, Share Data
Akari Therapeutics Plc, Major Products and Services
Akari Therapeutics Plc, History
Akari Therapeutics Plc, Key Employees
Akari Therapeutics Plc, Key Employee Biographies
Akari Therapeutics Plc, Key Operational Heads
Akari Therapeutics Plc, Other Locations
Akari Therapeutics Plc, Subsidiaries
Akari Therapeutics Plc, Key Manufacturing facilities
Akari Therapeutics Plc, Key Competitors
Akari Therapeutics Plc, SWOT Analysis
Akari Therapeutics Plc, Ratios based on current share price
Akari Therapeutics Plc, Annual Ratios
Akari Therapeutics Plc, Interim Ratios
Capital Market Ratios
Single User License:
Corporate User License:
select a license
NEWSLETTER BY CATEGORY
The report was very informative and gives me an interesting view on the Indian market.... "Area Sales Manager, Muhlen Sohn GmbH & Co. KG"
We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help... "Group Vice President Strategy, Aliaxis"
I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again... "Technical Marketing Manager, Ascendis Health Limited"
I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ... "., Coldwell Banker - Riyadh "
The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future... "International and Business Dev. Director, Duta Abadi Primantara"